AD: 2 × Phase II RCT—No cognitive benefit111 but reduced CSF Tau, pTau and biomarkers of synaptic health112.PD: No effect on depressive symptoms113. Mixed reports of effect on overall cognition113,114 Improved measures of executive dysfunction115. The gene discussed is MAPT; the disease is Parkinson disease.